BNR 外汇新闻

Burning Rock (BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, announced Tuesday that its OverC Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA), which is the third of its kind globally.